Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Intrathecal onasemnogene abeparvovec shows promise in older children with SMA
touchFEATURE
Start Learning
Streamlining Alzheimer’s disease diagnosis: The evolution of fluid biomarkers in clinical practice
Sponsored content
touchMEETING HIGHLIGHTS
Start Learning
Navigating BTK Dynamics in Multiple Sclerosis
Sponsored content
touchMEETING HIGHLIGHTS
Start Learning
Biomarkers of Smoldering Neuroinflammation in the Central Nervous System
Sponsored content
JOURNALS
Start Learning
Greatest Hits of 2024
JOURNALS
Start Learning
Future of Parkinson’s treatment: Gene therapy, DBS and symptom management
touchMEETING HIGHLIGHTS
Start Learning
Dissecting Drivers of Disability: A Scientific Exploration of the Central Nervous System Immune Microenvironment in Multiple Sclerosis
Sponsored content
touchIN CONVERSATION
Start Learning
Let’s talk about agitation in Alzheimer’s dementia: Prevalence, behavioural symptoms and reaching a diagnosis
CE/CME ACCREDITED
JOURNALS
Start Learning
Nipocalimab for generalized myasthenia gravis: First FcRn blocker approved for broad adult population
JOURNALS
Start Learning
Stroke Action Plan for Europe

to view Favourites, Keep Notes and Track CME Credits

Favourites
Individualized myasthenia gravis treatment based on well-defined disease pathogenesis
View
Prenatal treatment for SMA shows promise in groundbreaking case report
View
Shaping the future of MS care with Dr Bardia Nourbakhsh: touchNEUROLOGY Future Leader 2025
View
Nipocalimab for generalized myasthenia gravis: First FcRn blocker approved for broad adult population
View
Navigating BTK Dynamics in Multiple Sclerosis
View
Dr Amit Bar-Or receives prestigious 2025 John Dystel Prize for MS Research
View
Integrating the ALS genetic counseling and testing guidelines: considerations for your practice
View
CT1812 demonstrates promising biomarker data in Phase 2 SHINE study, AD/PD 2025
View
Valbenazine achieves sustained remission in majority of tardive dyskinesia patients in results from the KINECT 4 study
View
Early diagnosis and treatment of NMOSD: Practical insights
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup